BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1036 related articles for article (PubMed ID: 15347370)

  • 1. CD28 and secretory immunoglobulin A-dependent activation of eosinophils: inhibition of mediator release by the anti-allergic drug, suplatast tosilate.
    Woerly G; Decot V; Loiseau S; Loyens M; Chihara J; Ono N; Capron M
    Clin Exp Allergy; 2004 Sep; 34(9):1379-87. PubMed ID: 15347370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory effects of ketotifen on eotaxin-dependent activation of eosinophils: consequences for allergic eye diseases.
    Woerly G; Loiseau S; Loyens M; Schoch C; Capron M
    Allergy; 2003 May; 58(5):397-406. PubMed ID: 12752326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of the Th2 pathway by suplatast tosilate in patients with perennial nasal allergies.
    Furukido K; Takeno S; Ueda T; Hirakawa K; Yajin K
    Am J Rhinol; 2002; 16(6):329-36. PubMed ID: 12512908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of suplatast tosilate (IPD) with chloride channels in human blood eosinophils: a potential mechanism underlying its anti-allergic and anti-asthmatic effects.
    Agrawal DK; Cheng G; Kim MJ; Kiniwa M
    Clin Exp Allergy; 2008 Feb; 38(2):305-12. PubMed ID: 18028459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Inhibitory effect of suplatast tosilate on eosinophil migration].
    Kobayashi Y; Nagata M; Yamamoto H; Sakamoto Y
    Arerugi; 2000 Jul; 49(7):600-3. PubMed ID: 10944827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory effects of suplatast tosilate on the differentiation and function of monocyte-derived dendritic cells from patients with asthma.
    Tanaka A; Minoguchi K; Samson KT; Oda N; Yokoe T; Tazaki T; Yamamoto Y; Yamamoto M; Ohta S; Adachi M
    Clin Exp Allergy; 2007 Jul; 37(7):1083-9. PubMed ID: 17581203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beneficial effects of suplatast tosilate (IPD-1151T) in a rat cystitis model induced by intravesical hydrochloric acid.
    Kirimoto T; Nakano K; Irimura K; Hayashi Y; Matsuura N; Kiniwa M; Oka T; Yoshimura N
    BJU Int; 2007 Oct; 100(4):935-9. PubMed ID: 17714534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The inhibitory effect of anti-allergic agent suplatast tosilate (IPD-1151T) on methacholine- and allergen-induced bronchoconstriction in sensitized mice. asakazu@med.showa-u.dc.jp.
    Asano K; Mizutani T; Shimane T; Hisano M; Hisamitsu T; Suzaki H
    Mediators Inflamm; 2000; 9(2):77-84. PubMed ID: 10958380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kimura's disease associated with bronchial asthma presenting eosinophilia and hyperimmunoglobulinemia E which were attenuated by suplatast tosilate (IPD-1151T).
    Tsukagoshi H; Nagashima M; Horie T; Oyama T; Yoshii A; Sato T; Iizuka K; Dobashi K; Mori M
    Intern Med; 1998 Dec; 37(12):1064-7. PubMed ID: 9932643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of suplatast tosilate (IPD-1151T) on a mouse model of asthma: inhibition of eosinophilic inflammation and bronchial hyperresponsiveness.
    Zhao GD; Yokoyama A; Kohno N; Sakai K; Hamada H; Hiwada K
    Int Arch Allergy Immunol; 2000 Feb; 121(2):116-22. PubMed ID: 10705221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory effects of N-acetylcysteine on the functional responses of human eosinophils in vitro.
    Martinez-Losa M; Cortijo J; Juan G; O'Connor JE; Sanz MJ; Santangelo F; Morcillo EJ
    Clin Exp Allergy; 2007 May; 37(5):714-22. PubMed ID: 17456219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravesical suplatast tosilate (IPD-1151T) inhibits experimental bladder inflammation.
    Boucher W; Kempuraj D; Cao J; Papaliodis D; Theoharides TC
    J Urol; 2007 Mar; 177(3):1186-90. PubMed ID: 17296442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of suplatast tosilate on airway inflammation and airway hyperresponsiveness.
    Horiguchi T; Tachikawa S; Handa M; Hanazono K; Kondo R; Ishibashi A; Banno K
    J Asthma; 2001 Jun; 38(4):331-6. PubMed ID: 11456386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between interleukin-5 and eotaxin in regulating blood and tissue eosinophilia in mice.
    Mould AW; Matthaei KI; Young IG; Foster PS
    J Clin Invest; 1997 Mar; 99(5):1064-71. PubMed ID: 9062365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chronic eosinophilic pneumonia successfully treated with suplatast tosilate].
    Hamada H; Sakatani M; Nishioka M; Akira M; Yamamoto S; Ueda E; Okano Y; Nakamura Y; Sone S
    Nihon Kyobu Shikkan Gakkai Zasshi; 1997 Jun; 35(6):692-7. PubMed ID: 9294307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical suplatast tosilate (IPD) ameliorates Th2 cytokine-mediated dermatitis in caspase-1 transgenic mice by downregulating interleukin-4 and interleukin-5.
    Murakami T; Yamanaka K; Tokime K; Kurokawa I; Tsutsui H; Nakanishi K; Mizutani H
    Br J Dermatol; 2006 Jul; 155(1):27-32. PubMed ID: 16792748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The effect of suplatast tosilate on the patients with atopic dermatitis--relationship between clinical symptoms and immunological parameters].
    Higashi N; Niimi Y; Aoki M; Fujimoto K; Suzuki K; Numano K; Kawana S
    Arerugi; 2003 Nov; 52(11):1065-73. PubMed ID: 14685038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suplatast tosilate inhibits goblet-cell metaplasia of airway epithelium in sensitized mice.
    Shim JJ; Dabbagh K; Takeyama K; Burgel PR; Dao-Pick TP; Ueki IF; Nadel JA
    J Allergy Clin Immunol; 2000 Apr; 105(4):739-45. PubMed ID: 10756224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increase effect of transforming growth factor on eotaxin production by normal cultured dermal fibroblasts stimulated with interleukin-4: inhibitory effect of suplatast tosilate on eotaxin production.
    Bae SJ; Lee JB; Shimizu K; Kuwazuka Y
    Immunol Invest; 2010 Jan; 39(2):93-102. PubMed ID: 20136617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocyte growth factor suppresses production of reactive oxygen species and release of eosinophil-derived neurotoxin from human eosinophils.
    Ito W; Takeda M; Fujita M; Kamada Y; Kato H; Chiba T; Yamaguchi K; Ueki S; Kayaba H; Kanehiro A; Chihara J
    Int Arch Allergy Immunol; 2008; 147(4):331-7. PubMed ID: 18622140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.